Bayer HealthCare announced the launch of EZ-Log Web Client, a new online tool that allows hemophilia patients and healthcare providers to record and track treatment on the EZ-Log Web site. Now hemophilia patients have the convenience of two options to enter and transmit data within the EZ-Log system, the EZ-Log Web Client or the EZ-Log PDA – a hand-held device that allows patients to enter their treatment data in real-time by scanning barcodes of treatment packaging.
Together, the online and hand-held tools will make the EZ-Log Electronic Diary more accessible to hemophilia patients, helping to improve record-keeping compliance and communication between patients and healthcare professionals. To provide added convenience to both groups, EZ-Log Web Client is available to all hemophilia patients, regardless of their brand of treatment.
“With EZ-Log’s Web Client application, our clinic can use one program to manage treatment and monitor compliance for all our hemophilia patients, regardless of their treatment needs,” said Katie Westover, patient services coordinator, Milwaukee Comprehensive Center For Bleeding Disorders. “This tool gives us the ability to connect directly with individual patients electronically and allows patients to easily update their own records from anywhere.”
In addition to providing patients with a new tracking tool, Web Client offers added convenience to people living with hemophilia by giving them more communication choices to suit their busy lifestyles. Simple menus and icons make recording data fast and easy and personalized training ensures that patients will get the most out of the EZ-Log system.
The new features of the Web Client provide patients with:
– The added flexibility and convenience of using the technology they prefer to enter their infusion details, including the time, reason for infusion, and details of the bleed. Previously, electronic documentation of infusions was only possible through the hand-held device.
– A one-to-one messaging function that allows for personalized e-mail communications and automatic e-mail alerts between patients and healthcare providers. This new feature will also be available on the EZ-Log PDA.
– The ability to view reports that chronicle their infusion history displayed in either table, calendar, or graphical formats.
“We are pleased with the added convenience that Bayer’s new EZ-Log Web Client will provide for both patients and healthcare professionals,” said Terry Tenbrunsel, Vice President, Sales and Marketing, Bayer HealthCare. “We’re committed to continue providing more choices for those living with hemophilia while working with healthcare professionals to find new ways to help improve compliance.”
About Kogenate® FS
Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. Please see the full prescribing information for important risk and use information at kogenatefs.
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately one in 5,000 males born in the United States has hemophilia.
About Bayer HealthCare LLC
Bayer HealthCare LLC is an affiliate of Bayer HealthCare AG, one of the world’s leading, innovative companies in the healthcare and medical products industry based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women’s Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer HealthCare
View drug information on Kogenate FS.